IPG Investment Advisors LLC Acquires 70 Shares of Eli Lilly and Company (NYSE:LLY)

IPG Investment Advisors LLC boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 11.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 705 shares of the company’s stock after purchasing an additional 70 shares during the quarter. IPG Investment Advisors LLC’s holdings in Eli Lilly and Company were worth $331,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Silicon Valley Capital Partners bought a new stake in shares of Eli Lilly and Company in the 1st quarter worth approximately $25,000. Activest Wealth Management bought a new position in shares of Eli Lilly and Company during the 2nd quarter worth approximately $40,000. Laffer Tengler Investments bought a new position in shares of Eli Lilly and Company during the 1st quarter worth approximately $33,000. Raleigh Capital Management Inc. lifted its position in shares of Eli Lilly and Company by 156.4% during the 1st quarter. Raleigh Capital Management Inc. now owns 100 shares of the company’s stock worth $34,000 after buying an additional 61 shares during the period. Finally, Mitsubishi UFJ Morgan Stanley Securities Co. Ltd. acquired a new stake in Eli Lilly and Company during the 2nd quarter valued at $72,000. Institutional investors own 81.38% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on LLY. Argus upped their price objective on Eli Lilly and Company from $470.00 to $620.00 and gave the stock a “buy” rating in a research report on Tuesday, September 5th. Citigroup increased their target price on Eli Lilly and Company from $525.00 to $675.00 and gave the stock a “buy” rating in a research note on Monday, October 23rd. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Eli Lilly and Company in a research note on Wednesday, November 8th. UBS Group reiterated a “buy” rating and set a $710.00 target price (up previously from $612.00) on shares of Eli Lilly and Company in a research note on Friday, October 20th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $630.00 target price on shares of Eli Lilly and Company in a research note on Monday, October 23rd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and twenty have issued a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $557.00.

Eli Lilly and Company Trading Up 2.6 %

Shares of LLY stock opened at $613.17 on Tuesday. The stock’s fifty day moving average price is $575.93 and its two-hundred day moving average price is $504.72. The company has a market cap of $582.09 billion, a PE ratio of 111.08, a P/E/G ratio of 3.63 and a beta of 0.33. Eli Lilly and Company has a fifty-two week low of $309.20 and a fifty-two week high of $629.97. The company has a debt-to-equity ratio of 1.59, a quick ratio of 0.82 and a current ratio of 1.05.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be issued a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a dividend yield of 0.74%. The ex-dividend date is Tuesday, November 14th. Eli Lilly and Company’s dividend payout ratio is presently 81.88%.

Insider Activity at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 215,000 shares of the firm’s stock in a transaction on Wednesday, October 11th. The stock was sold at an average price of $605.44, for a total transaction of $130,169,600.00. Following the sale, the insider now owns 99,768,810 shares of the company’s stock, valued at approximately $60,404,028,326.40. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, CAO Donald A. Zakrowski sold 600 shares of the firm’s stock in a transaction on Monday, August 21st. The stock was sold at an average price of $546.51, for a total transaction of $327,906.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,378 shares of the company’s stock, valued at approximately $2,939,130.78. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Lilly Endowment Inc sold 215,000 shares of the firm’s stock in a transaction on Wednesday, October 11th. The stock was sold at an average price of $605.44, for a total value of $130,169,600.00. Following the transaction, the insider now directly owns 99,768,810 shares of the company’s stock, valued at $60,404,028,326.40. The disclosure for this sale can be found here. Insiders have sold a total of 536,138 shares of company stock valued at $20,881,627,358 in the last 90 days. 0.13% of the stock is owned by corporate insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.